204
Participants
Start Date
December 13, 2016
Primary Completion Date
June 16, 2020
Study Completion Date
November 24, 2020
Varlitinib
Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)
Cisplatin
On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine
Gemcitabine
On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.
Singapore
Seoul
Taipei
Lead Sponsor
ASLAN Pharmaceuticals
OTHER